Nasus Pharma, a clinical-stage pharmaceutical company specializing in intranasal drug products, announced its management will attend two investor conferences in New York on May 5 and May 7, 2026. CFO Eyal Rubin will hold one-on-one meetings to discuss the company's progress, including its lead product NS002, an intranasal epinephrine powder designed as a needle-free alternative for anaphylaxis treatment. This participation aims to engage investors ahead of pivotal clinical studies, emphasizing the potential of their proprietary powder-based intranasal technology for rapid drug delivery. Investors interested in meetings are advised to contact their representatives at sponsoring institutions.
The Schall Law Firm is investigating UP Fintech Holding Limited for possible securities law violations after a Reuters report revealed China's crackdown on illegal cross-border securities trading. The report accused UP Fintech's Tiger subsidiary of o...
Asset Workflows Ltd, a UK-based asset data management firm, received a major strategic investment led by CoMade and two healthcare investors. This funding will accelerate its expansion in Australia and the Asia-Pacific region, enhance product develop...
Talk of a Tesla-SpaceX merger is intensifying as Elon Musk moves closer to taking SpaceX public. The two companies already share engineering talent and collaborate on energy, computing, and infrastructure challenges. The potential deal is largely dri...
TIFIN.AI has launched TIFIN Australia, a new joint venture aimed at bringing advanced AI technology to the Australian wealth management market. Led by experienced executives Marcus Price and Justin Schmitt, the platform will offer AI-native solutions...
Agora, Inc. announced its Q1 2026 financial results with revenues rising 13.5% to $37.7 million and net income increasing to $1.1 million, marking its sixth consecutive quarter of GAAP profitability. The company launched Agent Studio, a no-code platf...
